Mikrobiomik Healthcare Company

mikrobiomik.net ↗ ·Derio ·Seed

Mikrobiomik is a Basque biopharmaceutical company that researches, develops and manufactures biological medicines based on the human gut microbiome, using its patented FSPIM full-spectrum intestinal microbiota technology. Its lead product, EUTEGRA (MBK-01), an oral lyophilised faecal microbiota capsule for recurrent Clostridioides difficile infection, received Spanish marketing approval in February 2026, making it the first authorised human microbiome therapy in Spain, with a launch planned for 2026 and European expansion (Italy, Germany, France) from 2027. It operates what it says is the first GMP facility dedicated exclusively to intestinal-microbiota medicines, has raised roughly €5-6M across successive small capital increases from Basque regional investors, family offices and equity crowdfunding, and has additional programmes in diverticulitis, liver cirrhosis, NASH and Klebsiella decolonisation. It is headquartered in Derio (Bizkaia, Basque Country).

Founded

2018

Founders

Total funds raised

€4.7M+

SectorsBiotech, Microbiome therapeutics, Pharmaceuticals, Healthtech Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Antonio Martínez-Martínez

Co-founder and board member

Guillermo Marco-Gardoqui

Co-founder and board member

Juan Basterra

Co-founder and former CEO / Director General

Global models 5

Vedanta Biosciences

United States · www.vedantabio.com ↗

Develops and makes its own oral gut-bacteria drugs (defined bacterial consortia), with the lead candidate targeting recurrent C. difficile infection.

$500MComparable

Finch Therapeutics

United States · www.finchtherapeutics.com ↗

Developed CP101, an oral capsule made from donor gut bacteria (whole microbiota), for recurrent C. difficile infection.

$150MComparable

Seres Therapeutics

United States · www.serestherapeutics.com ↗

Makes VOWST, an FDA-approved oral capsule made from donor gut bacteria for recurrent C. difficile infection; this is the closest match to EUTEGRA's approved-product model. The funding figure is VC raised before its IPO.

$130MComparable

MaaT Pharma

France · www.maatpharma.com ↗

European biotech making drugs from pooled donor gut bacteria (full-ecosystem microbiome therapies), with its own manufacturing and an early-access approval path.

$80MComparable

Rebiotix

United States · www.rebiotix.com ↗

Developed REBYOTA, a standardised drug made from donor gut bacteria for recurrent C. difficile, later acquired and brought to market by Ferring.

$40MComparable

In the same niche 67 others

See all in the Start-ups Map →

Highlight Therapeutics

+61 more →

Notes: Most funded first

Investors 4

Open as list →

Orza

www.orza.info

2 rounds, led 1 · 2019–23 Spain

Seed Capital Bizkaia

seedcapitalbizkaia.eus

2 rounds, led 1 · 2022–23 Spain

Capital Cell

capitalcell.com

Seed 2025 Spain

San Ignacio S.L.

Investor HQ unknown

Funding rounds 6

Date	Round	Amount	Lead
2025-09-30	Seed	€603K	Lead not disclosed +1 more
2025-03	Seed (estimated)	€1.6M	Lead not disclosed
2024-03	Seed (estimated)	€1M	Lead not disclosed
2023-09-25	Seed (estimated)	€1.1M	Lead not disclosed +2 more
2022-03-11	Seed	—	Seed Capital Bizkaia
2019-04-16	Pre-seed (estimated)	€400K	Orza

News

No coverage on record yet.